Literature DB >> 11751697

History about the discovery of the renin-angiotensin system.

N Basso1, N A Terragno.   

Abstract

The history of the discovery of the renin-angiotensin system began in 1898 with the studies made by Tigerstedt and Bergman, who reported the pressor effect of renal extracts; they named the renal substance renin based on its origin. In 1934, Harry Goldblatt induced experimental hypertension in dogs by clamping a renal artery. About 1936, simultaneously in the Medical School of the University of Buenos Aires, Argentina, and in the Eli-Lilly Laboratories in Indianapolis, 2 independent groups of researchers, using the Goldblatt technique to produce experimental hypertension, demonstrated renal secretion of a pressor agent similar to renin. In the following years, both teams described the presence of a new compound in the renal vein blood of ischemic kidneys. This agent was extracted from blood with 70% acetone and had a short pressor effect. The final conclusion was that renin acted enzymatically on a plasma protein to produce the new substance. In Buenos Aires, it was called hypertensin; in the United States, angiotonin. In 1958, Eduardo Braun Menéndez from Argentina and Irving H. Page from the United States agreed to name it angiotensin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751697     DOI: 10.1161/hy1201.101214

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  49 in total

1.  Tissue renin-angiotensin system and end-organ damage.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2002-04-12       Impact factor: 4.599

Review 2.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

3.  Antihypertensive medication prior to nocturnal sleep reduces the risk of new-onset type 2 diabetes in hypertensive patients: a role for slow-wave sleep?

Authors:  Christian Benedict
Journal:  Diabetologia       Date:  2016-02       Impact factor: 10.122

Review 4.  The intracrine renin-angiotensin system.

Authors:  Rajesh Kumar; Candice M Thomas; Qian Chen Yong; Wen Chen; Kenneth M Baker
Journal:  Clin Sci (Lond)       Date:  2012-09       Impact factor: 6.124

5.  Renin and cardiovascular disease: Worn-out path, or new direction.

Authors:  Gaurav Alreja; Jacob Joseph
Journal:  World J Cardiol       Date:  2011-03-26

6.  Angiotensin II acutely decreases myocardial stiffness: a novel AT1, PKC and Na+/H+ exchanger-mediated effect.

Authors:  Adelino F Leite-Moreira; Paulo Castro-Chaves; Pedro Pimentel-Nunes; Alexandre Lima-Carneiro; Miguel S Guerra; João Bruno Soares; João Ferreira-Martins
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 7.  Timing and selection for renal revascularization in an era of negative trials: what to do?

Authors:  Stephen C Textor; Michael M McKusick; Sanjay Misra; James Glockner
Journal:  Prog Cardiovasc Dis       Date:  2009 Nov-Dec       Impact factor: 8.194

8.  RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.

Authors:  Rukhsana Gul; Maya Ramdas; Chirag H Mandavia; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-10-27       Impact factor: 2.041

Review 9.  Vaccination: a novel strategy for inhibiting the renin-angiotensin-aldosterone system.

Authors:  Alan H Gradman; Rehka Pinto
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 10.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.